【04/24更新】今注目のグリー(株)【3632】、今後の値動きはどうなる？掲示板の反応まとめ。

こんな会社が時価総額1400億円近くあるのが不思議です。

【ゲーム株概況(4/26)】
Social Game Info - 4/26 18:50
URL: https://m.finance.yahoo.co.jp/news/detail/20210426-00000001-sgameinfo-bus_all

4月26日の東京株式市場では、日経平均は反発し、前日比105.60円高の2万9126.23円で取引を終えた。米国市場やアジア市場の上昇が市場心理の支えとなり、一時は上げ幅200円超に達する場面もあった。

相変わらずパッとしない銘柄ですね。

＞そろそろ売り枯れを期待したい時期なのですが、
＞連休前での処分売りが終わってからでしょうか。

今年の高値は635円。
売り枯れ＋増益発表＝目標635円以上

5月に期待です。

＞そろそろ売り枯れを期待したい時期なのですが、
＞連休前での処分売りが終わってからでしょうか。

今年の高値は630円。
売り枯れ＋増益発表＝目標630円以上

5月に期待です。

追加
はっきり分かっていること
ランキングが相当悪い 他社に比べ利益が少ない 日経な3万近いのに 600円以下
要するにボロ株でしょう

今夏配信予定

AIアプリきちゃ！？

＞MEMES/ミームズは、WFSが持つモバイルゲームの企画・開発・運営力、海外への展開力と、Preferred NetworksのAI技術、特に深層学習に関する知見や技術を組み合わせることにより、新たなデジタルエンターテインメント×AIの創出を目指したアプリケーションです。
www.wfs.games/memes

シドニアくらいは大きく宣伝を打ってもろて
とりあえず平均的な品質でリリースしたけど、全然広宣しないせいで話題にもならないというのはやめてもろて

社長のSNSアカウントあるんですね、知りませんでした。ありがとうございます！

しかし読んでみるとまー予想はしていましたが、あーなるほどITで一発吹かせた経営者がいかにも振りかざしそうなおセンチな経営哲学の講釈と言いますかなんと言いますか…残念な気持ちになりました。

10倍とか100倍とかまさに理想はその通りなのですが、現実問題として今の株価はピーク時からダラダラ下がって5分の1です。10倍100倍にするための具体的な成長戦略の発表もしていない中、SNSで呟いて何になるのでしょうか。

創業社長がやってる会社ってこういう感覚が浮世離れしてるから嫌いです。所有率数%の雇われ社長が同じこと呟いたら即解任でしょう。

名言・格言を残すには、まだ実績が足りない気がします。

古川とスリーダムの関係はこれ？

株式会社スリーダムは株式会社ABRIとの開発業務委託基本契約を締結しました
Conclusion of Development Consignment Fundamental Agreement with ABRI Co., Ltd.
株式会社スリーダムは株式会社ABRI（古河電池株式会社100％子会社、首都大学東京発ベンチャー）と「リチウムイオン電池及びリチウム金属電池の設計・開発」について開発業務委託基本契約を締結いたしました。

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

ヨーロッパ　サーｯカー

各国のトップチームだけで構成する　新しいトップリーグ創設が浮上し　あっちこっちで物議
イギリス議会でも激論

俺たちは「損切を競う　ハゲリーグだ」

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf
https://www.axcelead-hd.com/

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

PS3を姪っ子から強奪してきたからいまからFF13やろうと思うんだけど、ライトニングリータンって最初にやるの？最後にやるの？(´・ω・｀)
あとネバレタした奴まじでしばきぶち潰す

Pfizer and Japan set to agree a vaccine supply deal

Pfizer and Japan set to agree a vaccine supply deal

増やすの成功したかな

Crown Resorts Reaches Agreement With ILGA On Undertakings

お前らだから言うんだけど
グリーくるぞ(｀・ω・´)
根拠は勘だ(´･ω･｀)

スエズ運河が大混乱

>スエズ運河で渋滞を引き起こしたEVERGREENの後、再びイタリア船籍とギリシャ船籍の船が座礁し、
>運河は大混乱となっている。
>座礁したのは、イタリア船籍のRumfordとギリシャ船籍のMINERVA NIKEで、あいつぐ座礁は運河に
>砂が溜まったことも原因らしい。
>付近にはメディア王マードックや、元アマゾンCEOベゾスのクルーザーもあり、EVERGREENとの関係が
>取り沙汰されている。

マジかよ(´・ω・｀)

最近ハングリー精神ないし、だらけてるから田舎行って
修行してくる島根か鳥取あたりが候補。
周りにコンビニもないようなところ1か月の予定。

>>149
田舎出身って優秀な人多い。
一生田舎で暮らすのがいやでハングリー精神が違う